Publications, Abstract Presentations and Selected Research Initiatives

Andrew D. Luber, Pharm.D.

Original Articles

Luber AD, Condoluci D, Slowinski DP et al. Steady-state amprenavir and tenofovir pharmacokinetics after co-administration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2010. 11(3): 193-199.

Condoluci D, Andrew M, Luber A. Improvements in CD4 cell counts following the switch from tenofovir to abacavir in a patient with persistent lymphopenia despite continued non-detectable viral load measurements. AIDS Reader. 2008; 18: 410-412.

Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I. Steady state pharmacokinetics (PK) of QD fosamprenavir (FPV)/ritonavir (r) and atazanavir (ATV)/r alone and in combination with 20mg of omeprazole (OMP) in healthy volunteers. HIV Med. 2007. 8(7): 457-464.

Ruane P, Luber AD, Wire MB, Lou Y, Shelton M, Lancaster T et al. Plasma pharmacokinetics and tolerability of once-daily amprenavir, when administered as fosamprenavir, in combination with either 100mg or 200mg of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2007; 51(2); 560-565.

Guglielmo BJ, Luber AD, Paletta D, Jacobs RA. Ceftriaxone treatment of Staphylococcal osteomyelitis. Clin Infect Dis. 1999; 30: 205-207.

Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for Amphotericin-B induced nephrotoxicity. J Antimicrob Chemother. 1999; 43 (2): 267-271.

Guglielmo BJ, Luber AD, Corelli RL, Flaherty JF, Jacobs RA. Prevention of adverse events in hospitalized patients using an antimicrobial review program. West J Med. 1999; 171: 159-162.

Luber AD, Corelli, Flaherty JF, Kostiuk KA, Robinson M, Guglielmo BJ. The evolution of an antimicrobial review system at a university hospital. J Infect Dis Pharmacother. 1997; 2 (2): 65-90.

Luber AD, Flaherty JF. Famciclovir for treatment of herpesviruses. Ann Pharmacother. 1996; 30: 978-985.

Expert Reviews

Luber AD. Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2007: More Than It Seems? JIAPAC. 2008; 7:10.

Luber AD. The Use of Acid Reducing Agents (ARAs) in Protease Inhibitor (PI) Based HAART and the Potential for Negative Treatment Outcomes. AIDS Reader 2005; 15:692-695, 698-700.

Luber AD. Treatment strategies for heavily treatment experienced HIV infected patients: A focus on tipranavir. Expert Rev Anti Infect Ther. 2005; 3(5):815-823.

Luber AD. Genetic Barriers to Resistance and Impact On Clinical Response. Medscape MedJournal. July 2005. www.medscape.com/viewarticle/504524.

Luber AD. Double-Boosted Protease Inhibitors: An Emerging Therapeutic Strategy for HIV-Infected Patients - The Pharmacologic Basis for Double-Boosted PI Therapy. On-line at www.clinicaloptions.com/hiv/method/doubleboost. Posted June 2004.

Luber AD. Interactive Case Study: A treatment naïve patient infected with multi-drug resistant HIV. On-line: www.clinicaloptions.com/hiv/method/doubleboost. Posted June 2004.

Lalezari JP, Luber AD. Entry inhibitors for treatment of HIV: A new era in HAART. January 2004. On-line: www.HIVandHepatitis.com/essays/011904_hiv.html.

Lalezari JP, Luber AD. Enfuvirtide (T-20). Drugs Today. March 2004; 40 (3): 259-269.

Ruane PJ, Luber AD. New Developments in ARV Resistance: Tenofovir, K65R and Triple Nucleoside Regimens. Medscape General Medicine. April 2004; 6 (2): 31.

Ruane PJ, Luber AD. Possible causes of early treatment failure with a novel ARV regimen. Expert Column: Medscape HIV/AIDS (2). 2003. www.medscape.com/viewarticle/460673.

Becker SL, Luber AD. Therapeutic drug monitoring: Uses and misuses in clinical practice. 2002. Available online at http://www.medscape.com/viewarticle/424121.

Back D, Gatti G, Hoetelmans R, Fletcher C, Luber A, Kurowski M et al. Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002; 16 (suppl 1): S5-S37.

Luber AD. The push for once-daily HAART: A call for caution. www.HIV.medscape. June 2002.

Luber AD, Hardy WD. Therapeutic drug monitoring: Step by step. HIV/AIDS Annual Update 2001. iMedOptions, LLC; Milford, MA. Available online at http://hiv.medscape.com/update2001.

Luber AD, Hardy WD. Individualizing antiretroviral therapies for HIV-infected individuals using therapeutic drug monitoring: Are we there yet? HIVNewsline. February 2001.

Luber AD. To ABT or not to ABT: A re-evaluation of pharmacokinetics in HIV clinical practice. www.HIV.medscape.com. December 2000.

Luber AD. Human Immunodeficiency Virus: Practical treatment strategies for pharmacists. Calif J Health-System Pharm. 1997; 9 (2): 8-13.

Luber AD. Adefovir (PMEA) and adefovir dipivoxil (Bis-POM PMEA). Current drugs investigational drugs (on-line database). 1996.

Luber AD. Interactions with oral antibiotics. The Rx Consultant. December 1995. Vol IV (11).

Textbook Chapters

Ballard C, Caldwell B and Luber AD. Chapter 19. Principles of Applied Pharmacokinetics and Pharmacodynamics in Antiretroviral Therapy. In: AAHIVM Fundamentals of HIV Medicine. 2012.

Luber AD. Chapter 52: Research Design and Analysis. In: AAHIVM Fundamentals of HIV Medicine. 2012.

Luber AD. Chapter 53: Ethical Conduct of Clinical Trials, IRBS, Informed Consents and Financial Conflict of Interests. In: AAHIVM Fundamentals of HIV Medicine. 2012.

Luber AD. Editor. Journal of Viral Entry. April 2005-January 2011.

Luber AD. Pharmacology/Pharmacokinetic Sections: American Academy of HIV Medicine (AAHIVM) Self Study Accreditation Guide Updates. 2004-2008.

Luber AD. Pharmacology/Pharmacokinetic Sections: American Academy of HIV Medicine (AAHIVM) Self Study Accreditation Guide. 2003.

Luber AD. Pharmacotherapy of Human Immunodeficiency Virus. Chapter 69. In: Applied Therapeutics: The Clinical Use of Drugs. Koda-Kimble MA, Young L editors. 8th Edition. 2004.

Luber AD. Pharmacotherapy of Human Immunodeficiency Virus. Chapter 67. pp 67-1-67-37. In: Applied Therapeutics: The Clinical Use of Drugs. Koda-Kimble MA, Young L editors. 7th Edition. 2001.

Luber AD. Contribution Author: Clinical Cases: Clinical Pharmacy and Therapeutics Workbook for Herfindal and Gourley's Textbook of Therapeutics: Drug and Disease Management. 6th Edition. 1996.

Letters

Luber AD, Merry CA. Standard methods to measure HIV drug concentrations. Lancet. 2001; 358: 930.

Becker S, Fisher A, Flexner C, Gerber JG, Haubrich R, Kashuba A, Luber AD, Piscitelli S. Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: Call for consensus. JAIDS. 2001; 27: 210.

Luber AD, Dong BJ. Zidovudine use in HIV-infected pregnant females. Ann Intern Med. 2000; 132:509.

Barlows TG, Luber AD, Jacobs RA, Guglielmo BJ. Hypothermia following the intravenous administration of amphotericin B. Clin Infect Dis. 1996; 23 (5): 1187-1188.

Guglielmo BJ, Luber AD, Jacobs RA. Amphotericin-B induced hypothermia not proven – reply. Clin Infect Dis. 1997; 25: 757.

Luber AD, Jacobs RA, Jordan M, Guglielmo BJ. Relative importance of oral versus intravenous administration of vancomycin on the development of vancomycin-resistant enterococci. J Infect Dis. 1996; 173: 1292-1293.

Abstract Presentations

Luber A, Slowinski PD, Acosta E, Pakes G, Pappa K, Condoluci D. Steady-state pharmacokinetics (PK) of fosamprenavir (FPV) and raltegravir (RAL) alone and in combination with unboosted and ritonavir-boosted FPV. Abstract #1996. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15, 2009. San Francisco CA.

Luber A, Condoluci, D, Slowinski D, Louie S, Morwinkin N, Pappa K, Pakes. G. Steady-State Pharmacokinetics (PK) of Maraviroc (MVC) and Amprenavir (APV) Alone and in Combination After MVC is Given BID with Unboosted or Ritonavir (r)-boosted Fosamprenavir (FPV) Once- or Twice-daily in Fasted Healthy Volunteers. Presented at 10th International Workshop on Clinical Pharmacology of HIV Therapy. April 15-17, 2009. Amsterdam The Netherlands. Abstract P31.

Luber A, Slowinski D, Andrews M, Olson K, Peloquin C, Pakes G et al. Steady-State Pharmacokinetics (PK) of Tenofovir (TDF) and Fosamprenavir (FPV) After TDF is Given Once Daily (QD) With Unboosted or Ritonavir (r)-Boosted FPV Twice Daily (BID) in Healthy Volunteers. Presented at Eighth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. November 12-16, 2006.

Luber A, Brower R, Peloquin C, Frank I. Steady state pharmacokinetics (PK) of QD fosamprenavir (FPV)/ritonavir (r)) and atazanavir (ATV)/r alone and in combination with 20mg of omeprazole (OMP) in healthy volunteers. Presented at the 7th International Workshop on Clinical Pharmacology of HIV Therapy. April 20-22, 2006. Lisbon Portugal. Abstract 36.

Luber A, Ruane P, Peloquin C, Schutz M. Pharmacokinetic evaluation of duration of ritonavir (RTV) boosting among healthy volunteers taking once-daily saquinavir-ritonavir (SQV/r). Presented at the 7th International Workshop on Clinical Pharmacology of HIV Therapy. April 20-22, 2006. Lisbon Portugal. Abstract 44.

Luber A, Gharakhanian S, et al. Interactions entre médicaments modifiant l'acidité gastrique et inhibiteurs de la protéase chez des patients infectés par le VIH. Presented at Journées Nationales d'Infectiologie. June 2005. Nice France.

Condoluci D, Luber A, Folino M, Andrews M. CD4 Cell Count Declines Among Patients With Non-Detectable Viral Load Measurements Receiving Non-Didanosine (ddI) Containing, Tenofovir DF (TDF) Based HAART. Presented at the 6th International Workshop on Clinical Pharmacology of HIV Therapy. April 28-30, 2005. Quebec City, Quebec Canada.

Luber A, Garg V, Gharakhanian S et al. Survey of medications used by HIV-infected patients that affect gastrointestinal acidity and potential for negative drug-drug interactions with HAART. Presented at the 7th International Congress on Drug Therapy in HIV Infection. November 14-18, 2004. Glasgow Scotland.

Ruane P, Luber A, Wire MR, Lou Y, Shelton M, Lancaster C, Pappa K. Plasma amprenavir (APV) pharmacokinetics (PK) and safety following co-administration of fos-amprenavir (FPV) with a reduced ritonavir (RTV) dose once-daily (QD) (COL10053). Presented at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. October 29-November 2, 2004. Washington DC.

Ruane P, Luber A, Gaultier C, Stryker R, Anderson D, Peloquin C, Rothbard J. Maintenance therapy using lopinavir/ritonavir (LPV/r) alone for patients with well controlled HIV infection. Presented at 15th International AIDS Conference. July 11-16, 2004. Bangkok Thailand.

Ruane P, Luber A, Gaultier C, Anderson D, Stryker R, van Kempen A et al. Efficacy of trizivir (TZV) and tenofovir (TDF) as HAART for HIV-infected patients with current or underlying reverse transcriptase (RT) resistance. Presented at 15th International AIDS Conference. July 11-16, 2004. Bangkok Thailand.

Ruane P, Luber A, Gaultier C, Guyer B, Anderson D, Stryker R. Improvement in dyslipidemias and continued virologic suppression after substitution of PI or NNRTI with tenofovir (TDF) among patients receiving HAART. Presented at 15th International AIDS Conference. July 11-16, 2004. Bangkok Thailand.

Luber A, Anderson D, Stryker R, Hill A, Peloquin C, Boffito M, Ruane P. Can ritonavir (RTV) once daily boost saquinavir (SQV) twice daily? A pilot study. Presented at 15th International AIDS Conference. July 11-16, 2004. Bangkok Thailand.

Luber A, Anderson D, Stryker R, Hill A, Peloquin C, Boffito M, Ruane P. Can ritonavir (RTV) once daily boost saquinavir (SQV) twice daily? A pilot study. Presented at the 5th Inernational Workshop on Clinical Pharmacology of HIV. April 2004. Rome Italy.

Ruane P, Luber A, Akil B, Stryker R, Musikanth P, Defoto J et al., Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. Presented at the 2nd International AIDS Society Meeting. July 2003. Paris France.

Ruane P, Luber A, Gaultier C, Swaminathan S, Stryker R, Lanier R. Efficacy of trizivir (TZV) and tenofovir (TDF) as HAART for HIV infected patients with current or underlying reverse transcriptase (RT) resistance. Presented at the 2nd International AIDS Society Meeting. July 2003. Paris France.

Luber A, Lalezari J, Hitchcock M, Rooney J, Flaherty J. Drug-drug interaction study with intravenous cidofovir (CDV) and either trimethoprim/sulfamethoxazole (TMP/SMX), didanosine (ddI), or fluconazole (Flu) in HIV-infected individuals. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, CA September 2002.

Cimoch P, Ruane P, Tat SM, Luber A, Mathews C, Ballard C, Kakuda T. Safety and efficacy of lopinavir/ritonavir (LPV/r) and tenofovir disoproxil fumarate (TDF)-containing regimens in treatment experienced HIV-infected patients. XIV International AIDS Conference, Barcelona Spain. 2002

Gunawan S, Luber AD, Chaturvedi P, Griswold MP. Protease inhibitor drug level monitoring and differences between plasma and serum and assay matrixes for amprenavir (APV) levels in HIV-1 infected patients. 7th International Congress on Therapeutic Drug Monitoring and Clinical Toxicology. Washington DC. September 2001.

Luber AD, Stryker R, Burdick J et al. Efficacy of amprenavir (APV) 600mg plus low-dose ritonavir (RIT) in clinical practice. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK. October 2000.

Luber AD, Gunawan S, Lee S et al. Serum and plasma drug levels of amprenavir display limited inter- and intra-patient variability. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK. October 2000.

Luber AD, Shaker-Irwin L, Burdick J et al. Effects on cholesterol and triglyceride levels after switching from non-amprenavir protease inhibitor (PI) antiretroviral regimens to amprenavir (AMP) antiretroviral regimens. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada. September 2000.

Rice C, Luber AD, Pavlatos A et al. Lipo-accumulation among HIV-positive, protease inhibitor (PI) naïve patients receiving antiretroviral therapy. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada. September 2000.

Luber AD, Sherman M, Gotterer H, Shaker-Irwin L, Stryker R. Community collaborations between physicians and pharmacists improves adherence with HIV consensus panel guidelines and enhances the care of HIV-infected individuals. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 2000.

Grossman H, Luber AD, Purdom D et al. Response with twice-daily (BID) Crixivan plus Norvir based regimen (IDV-RIT) in patients failing protease inhibitor (PI) therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 2000.

Stryker R, Luber AD, Wolfe PR, Shaker-Irwin L, Cohan G. Lipoatrophy and lipo-accumulation disorders among HIV-infected individuals in a large urban HIV-practice. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 2000.

Thommes J.A, Luber AD, Burdick J, Shaker-Irwin L. Erythrocytosis following chronic androgen use in HIV-infected individuals. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 2000.

Luber AD, Mulnick J, Raber S, et al. Patient adherence with twice daily dosing of nelfinavir (NLF) equivalent to non-nucleoside reverse transcriptase inhibitors (NNRTI) when given in combination with dual nucleoside analogues (NRTI). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 2000.

Luber AD, Mulnick J, Raber S, et al. Patient adherence with twice daily dosing of nelfinavir (NLF) equivalent to non-nucleoside reverse transcriptase inhibitors (NNRTI) when given in combination with dual nucleoside analogues (NRTI). XIII International AIDS Conference. Durban, South Africa. July 2000.

Luber AD, Guglielmo BJ. Decision support systems via the use of interactive computer programs: Experience with an HIV treatment algorithm. Second Annual Workshop on Pharmaceutical Outcomes Research. Seattle, WA. May 2000.

Grossman H, Luber A, Purdom D et al. Salvage therapy with Indinavir 800mg plus Ritonavir 200mg (IDV/RTV) based regimens in clinical practice. Third International Workshop on Salvage Therapy for HIV Infection. Chicago, Ill. April 2000.

Luber AD, Gunawan S, Lee S et al. Serum drug levels of amprenavir display limited inter- and intra-patient variability. First International Workshop on Clinical Pharmacology of HIV Therapy. Noordjwick, Netherlands. March 2000.

Luber AD, Gasaway-Kilar J, Corelli RL, Guglielmo BJ, Koda-Kimble MA. A case-based, interactive computer program improves pharmacists' knowledge in antimicrobial pharmacotherapy. American College of Clinical Pharmacy (ACCP) Annual Meeting. Kansas City, KA. October 1999.

Guglielmo BJ, Paletta D, Luber AD, Jacobs RA. Once daily ceftriaxone for the outpatient treatment of Staphylococcus aureus osteomyelitis. Infectious Diseases Society of America (IDSA) Annual Meeting. Denver, CO. November 1998.

Luber AD, Gasaway-Kilar J, Corelli RL, Guglielmo BJ, Koda-Kimble MA. A case-based, interactive anti-infective computer program which mimics pharmacists' daily activities – Computer Software Demonstration. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Snowmass, CO. July 1998.

Guglielmo BJ, Maa L, Luber AD, Lam M. Risk factors for Amphotericin-B induced nephrotoxicity. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Canada. September 1997.

Luber AD, Dong BJ. Survey of physicians use of zidovudine in HIV infected pregnant females and their newborn infants. Fourth Conference on Antiretrovirals and Opportunistic Infections. Washington, DC. January 1997.

Guglielmo BJ, Corelli RL, Flaherty JF, Kostiuk KA, Luber AD, Robinson MD, Jacobs RA. An antimicrobial monitoring system improves therapeutic efficacy and reduces toxicity in

hospitalized patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Orleans, LA. September 1996.

Dong BJ, Luber AD. Survey of antiretroviral selections by physicians and HIV-infected individuals. XI International Conference on AIDS. Vancouver, Canada. July 1996.

Luber AD, Holtzer C, Dong D, Louie C. Evaluation of the number and types of overrides via an automated dispensing system. American Society of Health System Pharmacists (ASHP) Annual Meeting. San Diego, CA. June 1996.

Luber AD, Dong BJ. Summary of current recommendations on antiretroviral management in HIV infected individuals. California Society of Health-System Pharmacist (CSHP) Mid-Year Meeting. Palm Springs, CA. October 1995.

Selected Research Projects and Grants

2007 – *Co-Principal Investigator*. A Randomized, Open-label, Four-Arm, Three-Period, Drug Interaction Study to Assess Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics Following Co-administration of Fosamprenavir (FPV) 1400mg BID and RTG 400mg BID for 14 Days and Following FPV 700mg BID + RTV 100mg BID and RTG 400mg BID for 14 Days in Healthy Adult Subjects. (Investigator Initiated Trial). GlaxoSmithKline.

2006 – *Co-Principal Investigator*. Assessment of Nelfinavir (NLF) trough concentrations in the presence of the proton pump inhibitor omeprazole (OMP). (Investigator Initiated Trial). Pfizer Laboratories.

2005 – *Co-Principal Investigator*. Retrospective evaluation of CD4 cell counts among patients with non-detectable viral load measurements who are receiving non-ddI containing TDF based HAART. (Investigator Initiated Trial). No study sponsor.

2005 – *Co-Principal Investigator*. Evaluation of the steady state pharmacokinetics of amprenavir (when given as fos-amprenavir and fos-amprenavir/ritonavir) and tenofovir DF when given alone and together in healthy volunteers. (Investigator Initated Trial). GlaxoSmithKline.

2005 – *Co-Principal Investigator* – Evaluation of the duration of ritonavir activity on the pharmacokinetics of saquinavir in healthy volunteers following once-daily administration. (Investigator Initiated Trial). *Roche Pharmaceuticals.*

2005 – *Co-Principal Investigator.* Evaluation of steady state pharmacokinetics of fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with proton pump inhibitors among healthy volunteers. (Investigator Initiated Trial). *Vertex Pharmaceuticals.*

2004 – *Co-Principal Investigator*. Pharmacokinetic evaluation of duration of ritonavir boosting among HIV-infected patients taking twice-daily saquinavir-ritonavir. (Investigator Initiated Trial). *Roche Pharmaceuticals.*

2003 – *Co-Principal Investigator*. Evaluation of the anti-lipogenic effects of tenofovir DF (TDF) when combined with trizivir (zidovudine (AZT), lamivudine (3TC) and abacavir (ABC)) and combivir (zidovudine (AZT) and lamivudine (3TC). (Investigator Initiated Trial). *Gilead Sciences.*

2003 – *Co-Principal Investigator*. Evaluation of Combivir (Zidovudine (ZDV) plus Lamivudine (3TC)) in Combination With Tenofovir DF (TDF) Among Antiretroviral Treatment Naïve HIV-infected Patients. (Investigator Initiated Trial). *Gilead Sciences.*

2003 – *Sub Investigator*. A Phase I open-label, dose-escalation study of MDX-010 administered monthly as immunotherapy in patients infected with Human Immunodeficiency Virus. *Medarex Pharmaceuticals*.

2002 – *Principal Investigator*. "Pharmacokinetic evaluation of duration of ritonavir boosting among HIV-infected patients taking once-daily saquinavir-ritonavir." (Investigator Initiated Trial). *Roche Pharmaceuticals.*

2002 – *Co-Principal Investigator.* Viral dynamics of 3TC when given as once-daily monotherapy over 7 days. (Investigator Initiated Trial). *GlaxoSmithKline. .*

2002 – *Co-Principal Investigator.* Evaluation of maintenance therapy using lopinavir/ritonavir (LPV/r) alone for patients with well controlled HIV-infection. (Investigator Initiated Trial). *Abbott Laboratories.*

2002 – *Co-Principal Investigator.* Evaluation of switching tenofovir DF (TDF) for protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) agents among patients receiving HAART with non-detectable viral load measurements and elevated cholesterol and/or triglyceride values. (Investigator Initiated Trial). *Gilead Sciences.*

2002 – *Co-Principal Investigator.* Evaluation of trizivir (Zidovudine (ZDV), abacavir (ABC), lamivudine (3TC)) and tenofovir DF (TDF) as HAART for HIV infected patients with current or underlying reverse transcriptase (RT) resistance. (Investigator Initiated Trial). *GlaxoSmithKline.*

2002 – *Sub Investigator* - A phase I/II randomized, double-blind, active-controlled, dose escalation study of the safety, tolerance, pharmacokinetics, and antiviral activity of GS 7340-02 in antiretroviral-naïve patients who are chronically infected with HIV-1. *Gilead Sciences*.

2002 – *Co-Principal Investigator* – A multicenter Phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of S-1360 given as open-label monotherapy administered to treatment experienced HIV-1 infected subjects. *GlaxoSmithKline and Shionogi Pharmaceuticals*.

2002 – *Co-Principal Investigator* - A Phase II, randomized, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral doses of S-1360 versus placebo over 10 days in ART-naïve HIV-1 infected adults. *GlaxoSmithKline and Shionogi Pharmaceuticals*.

2002 – *Sub Investigator* - A Phase Ib double-blind, placebo-controlled, randomized study on the safety and tolerability of Z-100 in early HIV-1 infected patients. *Zeria Pharmaceuticals.*

2002 – *Sub Investigator* - A Phase II, open-label, multicenter, randomized, parallel group, 14 day pilot study of monotherapy with zidovudine 600 mg once daily compared to zidovudine 300 mg twice daily in HIV-infected, antiretroviral-naïve subjects. *GlaxoSmithKline.*

2001 – *Co-Principal Investigator* - A pharmacokinetic, safety and short-term efficacy study of amprenavir/saquinavir/ritonavir combination regimens for highly antiretroviral experienced HIV-infected individuals. (Investigator Initiated Trial). *Roche Pharmaceuticals.*

2001 – *Co-Principal Investigator* – Assessment of nelfinavir (NLF) peak and trough plasma levels among HIV-infected patients with stable but measurable viral load measurements between 1,000 and 5,000 copies/ml despite receiving dual nucleoside analogue therapy in combination with twice-daily NLF antiretroviral regimens. (Investigator Initiated Trial). *Agouron Pharmaceuticals.*

2001 – *Sub-Investigator* – A Phase II study evaluating the safety and efficacy of capravirine versus placebo in HIV-infected patients failing a non-nucleoside reverse transcriptase inhibitor containing regimen. *Agouron Pharmaceuticals*.

2001 – *Co-Principal Investigator* - Efficacy and tolerability of efavirenz (EFV) in highly antiretroviral experienced HIV-positive patients. (Investigator Initiated Study). *DuPont Pharmaceuticals.*

2000 – *Co-Principal Investigator* - Response with twice daily (BID) Crixivan® plus Norvir® based regimen (IDV-RTV) in patients failing protease inhibitor (PI) therapy. *Merck and Company.*

2000 – *Principal Investigator* - Effects on cholesterol and triglyceride levels after switching from non-amprenavir protease inhibitor (PI) antiretroviral regimens to amprenavir (APV) antiretroviral regimens. (Investigator Initiated Study). *Vertex Pharmaceuticals.*

2000 – *Principal Investigator* – Assessment of inter- and intra-patient amprenavir (APV) drug exposure when given as part of HAART. (Investigator Initiated Study). *Vertex Pharmaceuticals.*

2000 – *Co-Principal Investigator* – National survey of body habitus changes among HIV-positive, protease inhibitor (PI) naïve patients receiving antiretroviral therapy. (Investigator Initiated Study). *Agouron Pharmaceuticals.*

2000. *Principal Investigator* – A three center, prospective evaluation of patient adherence when taking twice-daily nelfinavir as compared to non-nucleoside reverse transcriptase inhibitor containing antiretroviral regimens. (Investigator Initiated Study). *Agouron Pharmaceuticals.*

1999. *Principal Investigator* – A prospective evaluation of the role of community pharmacists in the care of HIV-infected individuals. (Investigator Initiated Study). *Agouron Pharmaceuticals.*

1996 – *Sub-Investigator* – Drug-drug interaction study with intravenous cidofovir (CDV), and either trimethoprim/sulfamethoxazole (TMP/SMX), didanosine (DDI), or fluconazole (FLU) in HIV-infected individuals *Gilead Sciences*.

1995 – *Sub-Investigator* – A retrospective evaluation of once-daily ceftriaxone use in the treatment of *Staphylococcus aureus* osteomyelitis. (Investigator Initiated Study). *Roche Pharmaceuticals.*

1995 – *Sub-Investigator* – A retrospective evaluation of risk factors for amphotericin-B induced nephrotoxicity. (Investigator Initiated Study). *The Liposome Company.*

1995 – *Principal Investigator* – Development of an interactive case-based antimicrobial teaching tool. (Investigator Initiated Study). *Information Technology Grant, University of California San Francisco (UCSF).*

1994 – *Co-Principal Investigator* – National survey of antiretroviral therapy for HIV-infected individuals. (Investigator Initiated Study). *Brisol Myers Squibb.*